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Abstract
Introduction Currently, there is no adequate prevention or
treatment for both oral and gastrointestinal mucositis induced
by chemotherapy and/or radiotherapy. Supportive care of
symptoms plays a primary role during mucositis in the pedi-
atric clinical setting. We aimed to get insight in the currently
used feeding strategies in clinical practice in pediatric cancer
patients with chemotherapy-induced mucositis.
Methods A prospective observational study was performed to
identify feeding strategies after chemotherapy courses causing
mucositis in almost all patients at the University Medical
Center Groningen (UMCG), the Academic Medical Center
Amsterdam (AMC), and the Princess Maxima Center
Utrecht (PMC). Consecutive patients, aged 0–18 years, either
diagnosed with B cell non-Hodgkin lymphoma (B-NHL) or
scheduled for autologous stem cell transplantation (SCT) be-
tween April 2015 and September 2016 were included in this
study. In addition to the observational study in the
Netherlands, an international online questionnaire was con-
ducted for pediatric oncology centers.
Results A total of 13 patients were included, after 21 chemo-
therapy courses. No nutritional support was administered after
23.8% courses, tube feeding after 19.0% of the courses, TPN
in 19.0% of courses, and 38.1% received a combination of
tube feeding and TPN. The international survey revealed that
63.2% of the centers administered tube feeding as first choice,
31.6% administered only TPN as first choice, and one center
administered a combination as first choice.
Conclusions There is a variability in feeding strategies in the
clinical practice both in the Netherlands as well as worldwide.
This study is a basis for future studies in this important clinical
field to develop clinical trials comparing tube feeding and
TPN both in adult and pediatric patients.
Keywords Mucositis . Feeding strategy . Pediatric cancer
patients
Introduction
Mucositis is a severe side effect of both chemotherapy and
radiotherapy and can be subdivided in oral and gastrointesti-
nal (GI) mucositis. Patients suffering from GI mucositis have
symptoms like pain, vomiting, diarrhea, and a decreased in-
take, resulting in a decreased quality of life [1–3]. Moreover,
the patients are at increased risk to develop a bacteremia or
sepsis. Eventually, this may lead to a lower chemotherapeutic
dose or delay in the next chemotherapy course, possibly
influencing survival. Currently, there is no adequate
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prevention or treatment for both oral and GI mucositis. Only
supportive care of symptoms plays a primary role during mu-
cositis in the pediatric clinical setting [4]. During oral mucosi-
tis, the mouth is painful and oral intake may be difficult, but in
many patients, the intestine is still functioning and could be
used in, for example, enteral tube feeding [5]. However, during
GI mucositis, it is questionable if the intestine can still digest
and absorb the nutrients during mucositis. Previous clinical
studies have shown that at the time of mucositis, the absorption
of lactose is reduced, but amino acids can still be absorbed [6,
7]. Furthermore, from animal studies, we know that glucose
and amino acids could still be absorbed if enterally adminis-
tered continuously [8, 9]. In contrast, lactose and fatty acids
were not absorbed even if continuously administered enterally
[10, 11]. Even more, total enteral nutrition was not feasible,
and total parenteral nutrition (TPN) was superior to maintain
weight in rats [12]. Recently, it was shown that minimal enteral
feeding was feasible and possibly alters recovery after muco-
sitis in a rat model [13]. In general, nutritional support in pe-
diatric cancer patients is challenging, there is no consistency,
and both enteral nutrition and TPN have advantages and dis-
advantages [14, 15]. Tube feeding is not ideally during nausea
and vomiting. On the other hand, TPN may induce villus atro-
phy and mucosal permeability in the intestine [16–18].
Furthermore, adult patients with early initiated TPN had more
infections, 26 versus 22% and a higher incidence of cholestasis
[19]. Even more, liver dysfunction in critically ill patients de-
veloped in 30% in TPN patients versus 18% in patients with
enteral nutrition [20]. Unfortunately, no clinical studies have
been performed concerning nutritional support during mucosi-
tis [15]. Therefore, clinical trials concerning feeding strategies
during mucositis are needed. However, it is important to know
the current clinical practice in order to design clinical trials.
Therefore, we set up this research project to get insight in the
currently used feeding strategies in clinical practice in pediatric
cancer patients with chemotherapy-induced mucositis. We de-
termined the feeding strategy in a multicenter observational
study in the Netherlands prospectively. In addition, an online
survey was conducted among healthcare professionals interna-
tionally, to get more insight in the diagnosis and treatment
protocols of both oral and GI mucositis, and thereby determine
the differences and/or concordances between pediatric oncol-
ogy centers internationally.
Materials and methods
Observational study
Study and subjects
A prospective observational study was performed to identify
feeding strategies after chemotherapy courses causing
mucositis in almost all patients. The study was done at the
University Medical Center Groningen (UMCG), the
Academic Medical Center Amsterdam (AMC), and the
Princess Maxima Center Utrecht (PMC). Consecutive pa-
tients, aged 0–18 years, either diagnosed with B cell non-
Hodgkin lymphoma (B-NHL) or scheduled for autologous
stem cell transplantation (SCT) between April 2015 and
September 2016 were included in this study. Patients with
B-NHL were treated according to the Dutch Childhood
Oncology Group (DCOG) treatment protocol [21–24] and
were included after both COPADM1 and COPADM2 chemo-
therapy course. These two courses, consisting of vincristine,
methotrexate, cyclofosfamide, doxorubicin, and prednisone,
cause mucositis in almost all patients. Before stem cell trans-
plantation in, for example, neuroblastoma patients, the condi-
tioning regimen consisted of melphalan, etoposide, and
carboplatin according to treatment protocol NBL-2009 from
the DCOG [25], but other diagnoses with other conditioning
regimens were also included, as shown in Table 1. The
Medical Ethical Committee of the University Medical
Center Groningen, Groningen, The Netherlands, exempted
this study for ethical review board approval, since this study
observed the current clinical practice and data were generated
by routine medical care. For the use of the leftover material for
research purposes, all patients and/or parents signed informed
consent in general for the treatment protocol for their disease.
This study was registered in the online trial register (number
NTR5070).
Study procedures
When a patient was admitted in the UMCG, AMC, or PMC
for a chemotherapy course according to the treatment protocol
of B-NHL or for a conditioning regimen before autologous
SCT, the patient was eligible for inclusion. During admission,
the following items were registered after a chemotherapy
course daily: feeding strategy, weight, pain score, and muco-
sitis score. For the study purpose, nurses and doctors were
instructed to score on a daily basis the severity of mucositis
by using the National Cancer Institute Common Criteria for
Adverse Events (NCI-CTCAE) criteria for gastrointestinal
mucositis [26]. During admission, when regular blood sam-
pling was performed, the remaining plasma was used to mea-
sure citrulline. Citrulline is an amino acid, a marker for the
enterocyte mass corresponding with the severity of mucositis
in both adult and pediatric patients as well as with villus length
in a mucositis animal model [10, 27–32]. Therefore, with cit-
rulline, the level of mucositis could be checked during the
study period. No extra blood samples were taken for study
purpose only. The study ended when the patient was
discharged from the hospital or at time of start of the next
chemotherapy course.
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Data collection
Data collection included age, sex, chemotherapy course, daily
pain score (VAS score), daily mucositis score (NCI-CTCAE),
daily registration of tube feeding, and/or parenteral nutrition
administration. The use of analgesics, the number of
bacteraemias, and the duration of hospital stay in days were
looked up in the electronic patient record. Data were entered
on predesigned standardized case report forms and later cap-
tured into an electronic database.
Citrulline
The serum citrulline was measured by using automated ion
exchange column chromatography, as described before [10,
33, 34].
Online international survey
In addition to the observational study in the Netherlands, an
online questionnaire was conducted for pediatric oncology
centers (Supplementarymethods). The survey contained ques-
tions about the care of oral mucositis, the assessment/
diagnosis, prevention, treatment and pain management.
Secondly, the survey contained information about GI mucosi-
tis, concerning the diagnosis, assessment scale, biomarker,
nutritional support, prevention, treatment, and the use of pre-
biotics or probiotics. The survey was available online via a
link on the International Society of Pediatric Oncology (SIOP)
website. The survey was also distributed via SIOP and
Multinational Association of Supportive Care in Cancer
(MASCC) mailing lists.
Statistical analysis
Statistical analysis was done using SPSS version 22.0 for
Windows (SPSS Inc., Chicago, IL, USA). We used descrip-
tive statistics for all values, both in the prospective observa-
tional study and in the international survey. All values ex-
press mean and standard deviation if parameter is normal
distributed. Non-parametrical data are expressed as median
and range.
Results
Prospective observational study
Patient characteristics
A total of 13 patients were included, after 21 chemotherapy
courses as shown in Table 1. The median age was 11 (1–18)
years, and most patients were male (84.6%). Before start of
the chemotherapy course, five patients already received nutri-
tional support which was tube feeding in all cases. All five
patients with B-NHL and one patient with systemic EBV + T
cell lymphoproliferative disease of childhood, treated accord-
ing to the B-NHL protocol, were included after both
COPADM1 and COPADM2 course. Patients scheduled for
an autologous stem cell transplantation (SCT) were included
after the conditioning regimen (n = 7). Two patients received a
second SCT and were therefore included twice, after both
conditioning regimens.
Feeding strategy
In one center, it was standard care to start with TPN after
stem cell reinfusion in every patient, independent of the
nutritional status, and tube feeding was only added when
the patients’ clinical condition improved and they could
tolerate enteral feeding. In all other patients and in the two
other centers, it was standard care to start with tube feeding
in case of decreased oral intake, and TPN was only admin-
istered if tube feeding was not tolerated due to vomiting,
abdominal discomfort, or diarrhea. The feeding strategy
was very diverse as shown in Table 2 and Fig. 1. No
Table 1 Patient characteristics
Characteristic
Patients, n 13
Chemotherapy courses, n 21
Age, median (range) 11 (1–18)
Sex
Male, n (%) 11 (84.6)
Diagnosis
B-NHL 5
Systemic EBV + T cell lymphoproliferative
disease of childhooda
1
Neuroblastoma 2
Relapse ewing sarcoma 1
Medulloblastoma 1
Glioma 1
Relapse Hodgkin lymphoma 1
Relapse Wilms tumor 1
Chemotherapy courses
COPADM1, n (%) 6 (28.6)
COPADM2, n (%) 6 (28.6)
Conditioning regimen for SCTb, n (%) 9 (42.8)
Tube feeding before chemotherapy, n (%) 5 (23.8)
B-NHL B cell non-Hodgkin lymphoma, SCT stem cell transplantation
a Treatment according to the B-NHL protocol with COPADM1 and
COPADM2 courses
b Two patients received two times a SCT and were therefore included
twice
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nutritional support was administered after 23.8% courses.
After 19.0% of the chemotherapy courses, only tube feeding
was administered. After 19.0% of the courses, only TPN
was administered, of which three patients in the center
where it was standard care to start TPN after stem cell rein-
fusion and one based on patient preferences. The nutritional
support administered after most courses, 38.1%, was a com-
bination of tube feeding and TPN, of which after seven
courses as first step, tube feeding was started, and secondly,
TPN was added because total enteral tube feeding was not
tolerated. After one course, first TPN was started, and then,
as second step, tube feeding was added when the patient
tolerated enteral feeding.
Nutritional status
Figure 2 shows the largest bodyweight change after a chemo-
therapy course in percentage compared with the bodyweight
before a chemotherapy course. As shown, in most patients
without nutritional support or with tube feeding alone, there
was a decrease in bodyweight. Nine patients receiving either
TPN or tube feeding + TPN seemed to increase in bodyweight,
without another specific reason to declare the remarkable in-
crease in bodyweight. This may be due to either overfeeding or
an increase in fluids because of increased illness.
Mucositis and pain score
The median highest mucositis score after chemotherapy
courses was 3 (1–4). The median highest pain score after
chemotherapy courses, specifically abdominal pain, was 3
(0–9). Furthermore, pain medication was administered after
20 courses (95.2%), as shown in Table 2. Proportionally, the
most morphine was administered in the group where the com-
bination of tube feeding + TPN was administered, suggesting
that these patients suffered from more severe mucositis.
Citrulline
Figure 3 shows the lowest plasma citrulline levels measured
between day 5 and day 13 after the chemotherapy course.
Most patients receiving TPN or tube feeding + TPN had a
lowest citrulline level below 10 μmol/l, reflecting severe mu-
cositis, of which most received a conditioning regimen [35].
Infections
The patients developed fever and were consequently treated
with ceftazidim and/or vancomycin after 14 (66.7%) chemo-
therapy courses, as shown in Table 2. Patients with TPN had
more episodes of fever with antibiotic treatment (n = 10)
Table 2 Feeding strategy
No
nutritional
support
(n = 5)
Tube feeding
(n = 4)
TPN
(n = 4)
Tube feeding + TPN
(n = 8)
Total courses
(n = 21)
Age, median (range) 13 (11–15) 10.5 (10–15) 13 (10–18) 6 (1–16) 11 (1–18)
Highest mucositis score, median (range) 2 (1–3) 1.5 (1–2) 1 (1–3) 3 (2–4) 3 (1–4)
Highest pain score, median (range) 0 (0–4) 3 (0–6) 2 (0–8) 7 (3–9) 3 (0–9)
Pain medication
Paracetamol, n (%) 5 (100%) 4 (100%) 3 (75%) 8 (100%) 20 (95.2%)
Tramadol, n (%) 4 (80%) 3 (75%) 1 (25%) 6 (75%) 14 (66.7%)
Morphine, n (%) 1 (20%) 1 (25%) 2 (50%) 6 (75%) 10 (47.6%)
Other, n (%) 0 (0%) 1 (25%) 1 (25%) 4 (50%) 6 (28.6%)
Vomiting, n (%) 0 (0%) 1 (25%) 1 (25%) 3 (37.5%) 5 (23.8%)
Diarrhea, n (%) 0 (0%) 1 (25%) 0 (0%) 5 (62.5%) 6 (28.6%)
Episode with fever for which treatment
with ceftazidim and/or vancomycin, n (%)
3 (60%) 1 (25%) 3 (75%) 7 (87.5%) 14 (66.7%)
After start of TPN 3 4
Before start of TPN 2
Simultaneously with start of TPN 1
Positive blood culture, n (%) 2 (40%) 0 (0%) 1 (25%) 3 (37.5%) 6 (28.6%)
Hospital stay after chemotherapy course in days,
mean ± SD
13.8 ± 2.4 11 ± 4.3 15.5 ± 2.1 17.5 ± 5.9 15 ± 4.9
Tube feeding pain score n = 3, mucositis score n = 2, tube + tpn pain score n = 7
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versus patients without TPN (n = 4), but only slightly more
positive blood cultures (n = 4 versus n = 2, respectively). The
episodes of fever developed after start of TPN in seven pa-
tients, in two patients before the start of TPN and in one
patient simultaneously with the start of TPN. Furthermore,
patients receiving TPN were hospitalized for more days after
the chemotherapy course compared to patients without TPN
(mean 16.8 ± 4.9 versus 12.6 ± 3.8 days).
Online international survey
Twenty healthcare professionals specialized in mucositis care
in pediatric cancer patients completed the online survey. Most
professionals were pediatric oncologists (n = 15), two nurses,
two pharmacists in pediatric oncology, and one radiation on-
cologist. Most were working in a pediatric oncology depart-
ment in Europe (n = 13), three in Northern America, two in
South America, and two in Arabia.
Assessment scale to diagnose oral mucositis
To diagnose oral mucositis, 15/20 of the hospitals used an as-
sessment scale, mostly the NCI-CTCAE (33.3%), WHO scor-
ing scale (33.3%), and ChIMES self-scoring scale (13.3%), 1
combines the NCI-CTCAE and the WHO scale (6.7%), and 2
hospitals use their own developed scoring scale (13.3%).
Pain medication during oral mucositis
Mostly used pain medication during oral mucositis is mor-
phine (85%), paracetamol (55%), tramadol (40%), and topical
pain medication like mouthwash containing lidocaine (25%),
and a minority also uses NSAIDs (10%) as analgesia during
oral mucositis.
Prevention and treatment of oral mucositis
The most prevalent intervention as prevention is mouthwash
(50%) and oral cryotherapy (20%). In 7/20 centers (35%), no
prevention is given. For treatment of oral mucositis, interven-
tions like mouthwash (35%) and low-level laser therapy (5%)
are used. In 10/20 centers (50%), no intervention is used as
treatment.
Diagnosis of gastrointestinal mucositis
In 14/20 centers (70%), the diagnosis of GI mucositis is only
based on clinical symptoms like vomiting, abdominal discom-
fort, and diarrhea. Some centers (20%) combine the clinical
Fig. 1 Feeding strategy. Feeding
strategy after the chemotherapy
course. The bars represent the
number of days the nutritional
support was administered. Every
row represents one course.
Twenty-one courses in total. After
five COPADM courses, no
nutritional support was
administered
Support Care Cancer
symptoms with the NCI-CTCAE scoring scale. One center
combines the clinical symptoms with the daily gut score.
One center combines the clinical symptoms with the NCI-
CTCAE score and fecal calprotectin as biomarker.
Feeding strategy during GI mucositis
Nineteen of 20 respondents answered the questions about nu-
tritional support as shown in Fig. 4. In 13/19 centers, tube
feeding is administered as first choice for nutritional support
during mucositis and parenteral nutrition as second choice. In
3/19 centers, they administer parenteral nutrition as first
choice and tube feeding as second choice; all of these centers
are located in Northern America. Two centers, in Spain and
Macedonia, do not administer tube feeding at all, only paren-
teral nutrition. One center chooses directly for a combination
of both as nutritional support. If tube feeding is administered,
in 5/19, this is the normal standard diet. In 8/19 centers, a
semi-elemental diet is given as tube feeding. Two centers ad-
minister elemental diet. Two centers are not sure, and in two
centers, it is the decision of the dietician. If parenteral nutrition
is administered, 12/19 centers add minimal enteral feeding
(MEF) via tube. Three centers administer MEF sometimes,
and four centers do not administer MEF as additive to paren-
teral nutrition.
Prebiotics or probiotics
Four centers administer prebiotics or probiotics occasionally,
for example, Linex® or Biopron®, but the majority does not
administer any prebiotic or probiotic.
Discussion
This is the first study addressing nutritional support during
chemotherapy-induced mucositis and aimed to get insight in
the current feeding strategy during chemotherapy-induced
mucositis in pediatric cancer patients. Our results showed
the variability in feeding strategies concerning tube feeding,
TPN, type of diet, and administration of MEF. There is no
consensus between centers in the Netherlands or worldwide.
The feeding strategy is currently dependent on patients and
doctors’ preferences.
This observational study showed that within three centers
in the Netherlands, there was already a different standard care
for nutritional support during mucositis. The results showed
that one center started TPN in all patients receiving stem cell
transplantation and only added tube feeding after the patient
improved his/her blood count and tolerated enteral feeding. In
all other cases, nutritional support was only administered in
case of a decrease in bodyweight. The first choice in all cen-
ters was tube feeding, and TPN was only added in case of
intolerance of total tube feeding, for example, due to vomiting.
Although it is only an explorative study, the results may give a
few suggestions. First, the results suggest that TPN caused a
better nutritional status after chemotherapy courses, compared
to the weight loss when no nutritional support or tube feeding
only was administered. Secondly, in contrast, the results sug-
gest that the administration of TPN was associated with more
episodes of fever for which antibiotic treatment was started. In
most of these cases, fever with antibiotic treatment developed
after the start of TPN. Furthermore, patients receiving TPN
Fig. 3 Plasma citrulline. Lowest plasma citrulline measured in the days
after chemotherapy treatment. Each dot represents individuals after
chemotherapy treatment. The line is the median per feeding strategy.
All samples were measured between day 5 and day 13 after
chemotherapy course
Fig. 2 Bodyweight change. Largest bodyweight change in days after
chemotherapy course, in percentage compared to bodyweight prior to
chemotherapy. Between day 1 and day 11. The line is the median. Dots
represent individuals after chemotherapy course
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were hospitalized for more days after chemotherapy compared
to patients without TPN. The pain medication and citrulline
levels suggested more severe mucositis in the patients receiv-
ing TPN. Therefore, this suggests that the patients receiving
TPN were more severely ill, which might have contributed to
the prolonged hospitalization.
The results from the survey, although a small number of
centers participated, also suggest that there are intercenter dif-
ferences in feeding strategies. Tube feeding, TPN, or a com-
bination of both are all first choice as nutritional support.
Furthermore, in the majority of centers, minimal enteral feed-
ing is added to TPN if it is feasible; however, a few centers do
not administer tube feeding at all. Moreover, the result show
that also in pain management, there are many differences be-
tween centers.
Since this was the first study concerning feeding strategies
during mucositis, we could not compare the results to other
studies in patients with mucositis. However, in a systematic
review concerning critically ill pediatric patients, it was also
concluded that there was a lack of data and the main conclu-
sion was that research is urgently needed [36]. Recently, one
study determined the difference between early and late paren-
teral nutrition in critically ill pediatric patients. They showed
that late parenteral nutrition was superior, for, among other
things, less new infections and a shorter duration hospital stay
[37]. This is comparable to the suggestions of our results.
Furthermore, in children undergoing allogeneic hematopoietic
stem cell transplantation, not specifically during mucositis,
enteral nutrition is suggested to be the first option and paren-
teral nutrition the second [38]. Additionally, a systematic re-
view concerning nutritional support in children with cancer
receiving chemotherapy, not specifically mucositis, suggested
that TPN might be superior compared to normal food intake
[39]. However, not one study compared tube feeding with
TPN, and the main conclusion was that further research is
essential.
A limitation of this study is that it was only an observa-
tional study in a small amount of patients, in which we were
not able to do an appropriate analysis, but only descriptive
statistics. We were therefore not able to draw conclusions
about the best feeding strategy during mucositis, both in the
observational study as well as the survey. However, we
aimed to show the currently used feeding strategies in the clin-
ical practice in pediatric cancer patients with chemotherapy-
induced mucositis. Therefore, this study may contribute to the
design of clinical trials comparing feeding strategies and even-
tually the development of guidelines to improve the clinical
practice.
In conclusion, since there are both discordances in the clin-
ical practice in the Netherlands and worldwide, as well as a
lack of knowledge, we are in need of a clinical trial concerning
feeding strategies duringmucositis. In the meantime, based on
our results in combination with literature, we suggest to ad-
minister tube feeding as first choice, with an easy access to
TPN in case of decreased nutritional status or intolerance for
a
b
c
Fig. 4 Feeding strategy during mucositis. In 19 centers worldwide. a
Survey question: What is the first choice of nutritional support? b
Survey question: Which diet is administered as tube feeding. c Survey
question: Is minimal enteral feeding administered as additive to total
parenteral nutrition?
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tube feeding. Although TPNmay be effective to stay in a good
nutritional condition, we suggest to be careful to introduce
TPN as first option as feeding strategy since it possibly in-
creases the risk for infection. However, further research is
needed to draw conclusions. Therefore, this study is a basis
for future studies in this important clinical field to develop
clinical trials comparing tube feeding and TPN both in adult
and pediatric patients.
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